The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 08, 2020

Filed:

Jul. 18, 2016
Applicants:

Nicole Suciu-foca, New York, NY (US);

George Vlad, Forest Hills, NY (US);

Zheng Xu, New York, NY (US);

Inventors:

Nicole Suciu-Foca, New York, NY (US);

George Vlad, Forest Hills, NY (US);

Zheng Xu, New York, NY (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01); A61K 38/17 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); A61K 38/1774 (2013.01); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); G01N 33/574 (2013.01); G01N 33/57492 (2013.01); C07K 2317/76 (2013.01); G01N 2800/52 (2013.01);
Abstract

It has now been discovered that activated lymphocyte cell adhesion molecule (ALCAM)—also known as CD166—is the ligand of the innate immune receptor ILT3 that is expressed by DC and monocytes. It has been further discovered that the specific binding of ILT3 to its ligand CD166 on the surface of CD166-expressing cancer cells, arrested cancer cell growth and initiated apoptosis. Therefore, certain embodiments relate to methods and compositions for treating CD166-expressing cancers by administering ILT3Fc, full-length ILT3 or any CD166 ligand-binding fragment thereof.


Find Patent Forward Citations

Loading…